CQDM invites you to its next Connect-BIO, a must-attend event bringing together researchers and entrepreneurs to discuss the future of preclinical research, focused on innovative and responsible approaches aimed at reducing the use of animals.<\/p>\n\n\n\n
On the agenda:<\/strong> Co-founder and Partner at Linearis<\/strong>, Alexandre Le Bouthillier brings over 20 years of experience in IT and artificial intelligence to enhance healthcare diagnostics and treatments. Holding a Ph.D. in Computer Science from Universit\u00e9 de Montr\u00e9al, he serves on the boards of Mila<\/strong>, IVADO<\/strong>, MEDTEQ+<\/strong>, envisAGE<\/strong>, and Montr\u00e9al InVivo<\/strong>. A visionary leader, he is dedicated to building a collaborative and sustainable health ecosystem.<\/p>\n\n\n\n Dr. Dean Smith<\/strong>, Senior Scientific Advisor at Health Canada<\/strong>, has over 25 years of experience in research and regulatory science focused on biologics and vaccines. He represents Health Canada at the WHO<\/strong> and the European Directorate for the Quality of Medicines<\/strong>, contributing to the development of international guidance. An immunologist by training, his research at the University of Alberta explored vaccine antigens and gene therapy approaches.<\/p>\n\n\n\n Dr. Margaret Magdesian<\/strong>, Founder and CEO of Ananda Devices<\/strong>, develops groundbreaking technologies to reduce animal use in neurological research. Her collaboration with the U.S. FDA<\/strong> led to the qualification of a New Approach Method (NAM) replacing mouse bioassays. Winner of 27 international awards<\/strong>, she serves on several scientific boards and actively champions women in science and entrepreneurship.<\/p>\n\n\n\n As CEO of Epiloid Biotechnology<\/strong>, Dr. Mark Aquilino<\/strong> is a biomedical engineer specializing in 3D tissue engineering and machine learning applied to preclinical research. His work integrates human electrophysiology with brain organoid models to accelerate drug discovery. He operates at the intersection of science, innovation, and entrepreneurship.<\/p>\n\n\n\n Dr. Vincent Ling<\/strong>, Chief Business Officer at Morphocell Technologies<\/strong>, brings over 30 years of experience in biotechnology and pharmaceutical development. He has led teams in stem cell biology, genomics, and regenerative medicine at companies including Takeda<\/strong>, Wyeth<\/strong>, and Neurotech<\/strong>. His expertise bridges science, strategy, and innovation in health.<\/p>\n\n\n\n
\ud83d\udd2c Hear from renowned expert speakers
\ud83d\udcac Engage in discussions, ask questions, and expand your knowledge
\ud83e\udd1d Wrap up the day with a networking cocktail \u2014 a great opportunity to grow your network and connect with the ecosystem, generously offered by our partner ROBIC<\/p>\n\n\n\n\ud83c\udf99\ufe0f Panelists<\/strong><\/h3>\n\n\n\n
Alexandre Le Bouthillier, Ph.D.<\/strong><\/h4>\n\n\n\n
Dean K. Smith, Ph.D.<\/strong><\/h4>\n\n\n\n
Margaret Magdesian, Ph.D.<\/strong><\/h4>\n\n\n\n
Mark Aquilino, Ph.D.<\/strong><\/h4>\n\n\n\n
Vincent Ling, Ph.D.<\/strong><\/h4>\n\n\n\n